Results 1 to 10 of about 40,241 (253)
Journal of the European Academy of Dermatology and Venereology, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+13 more sources
Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: A budget impact analysis using a Delphi panel [PDF]
, 2017 Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with ...
Arnold G. Vulto +5 more
core +7 more sources
Lupus, 2020 Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising
Christopher J Edwards +1 more
+6 more sources
PLoS ONE, 2023 Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic.
Thomas M Herndon +11 more
semanticscholar +1 more source
WHO guidelines on biosimilars: Toward improved access to safe and effective products
Annals of the New York Academy of Sciences, 2023 The World Health Assembly resolution on access to biotherapeutics in 2014 urges WHO and Member States to facilitate access to biotherapeutics while ensuring their quality, safety, and efficacy.
Hye-Na Kang +4 more
semanticscholar +1 more source
Navigating adalimumab biosimilars: an expert opinion
Journal of Comparative Effectiveness Research, 2023 The patent expiry of Humira® in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita®, Amsparity®, Hulio®, Hukyndra®, Hyrimoz®, Idacio®, Imraldi® and Yuflyma® – for the treatment of various immune ...
V. Abitbol +3 more
semanticscholar +1 more source
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars
Journal of Managed Care & Specialty Pharmacy, 2023 BACKGROUND: Few surveys about biosimilars have been conducted among US patients. OBJECTIVE: To evaluate attitudes about biosimilars among patients with rheumatoid arthritis (RA), psoriasis and/or psoriatic arthritis (PsO/A), and/or inflammatory bowel ...
A. Gibofsky +6 more
semanticscholar +1 more source
Frontiers in Bioengineering and Biotechnology, 2022 Biopharmaceuticals are one of the fastest-growing sectors in the biotechnology industry. Within the umbrella of biopharmaceuticals, the biosimilar segment is expanding with currently over 200 approved biosimilars, globally. The key step towards achieving
N. Nupur +3 more
semanticscholar +1 more source
Drug Safety, 2023 Biosimilars are additional treatment options that are approved based on robust analytical and clinical comparisons with their reference biologic. At the time of initial approval, the full safety profile of a biosimilar is inferred from the reference ...
Sreedhar Sagi +4 more
semanticscholar +1 more source
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]
, 2020 ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick +8 more
core +1 more source